Insights into melanoma: targeting the mTOR pathway for therapeutics (Q38012466)

27 August 2017

title

Insights into melanoma: targeting the mTOR pathway for therapeutics (English)

1 reference

27 August 2017

2

1 reference

27 August 2017

0 references

Helena Pópulo

1

1 reference

27 August 2017

José Manuel Lopes

series ordinal

3

1 reference

27 August 2017

language of work or name

English

0 references

publication date

24 May 2012

1 reference

Expert Opinion on Therapeutic Targets

27 August 2017

published in

1 reference

27 August 2017

volume

16

1 reference

27 August 2017

issue

7

1 reference

27 August 2017

page(s)

689-705

1 reference

Human melanocyte biology, toxicology, and pathology

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Global perspectives of contemporary epidemiological trends of cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Melanoma genetics and the development of rational therapeutics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Risk of cutaneous melanoma associated with pigmentation characteristics and freckling: systematic overview of 10 case-control studies. The International Melanoma Analysis Group (IMAGE).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Naevi and pigmentary characteristics as risk factors for melanoma in a high-risk population: a case-control study in New South Wales, Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Cutaneous melanoma: prognosis and treatment results worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Final version of 2009 AJCC melanoma staging and classification

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Distinct sets of genetic alterations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The Rb family connects with the Tp53 family in skin carcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

High-risk Melanoma Susceptibility Genes and Pancreatic Cancer, Neural System Tumors, and Uveal Melanoma across GenoMEL

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Lifetime risk of melanoma in CDKN2A mutation carriers in a population-based sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Mammalian cyclin-dependent kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Genetics of melanoma predisposition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Contribution of melanocortin-1 receptor gene variants to sporadic cutaneous melanoma risk in a population in central Italy: a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

CDKN2A common variant and multi-organ cancer risk--a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The melanocortin-1 receptor: red hair and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

ARF functions as a melanoma tumor suppressor by inducing p53-independent senescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The genome and epigenome of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Deregulated Akt3 activity promotes development of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

High frequency of BRAFV600E mutation in acquired nevi and small congenital nevi, but low frequency of mutation in medium-sized congenital nevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Analysis of mutations in B-RAF, N-RAS, and H-RAS genes in the differential diagnosis of Spitz nevus and spitzoid melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

V599EB-RAF is an oncogene in melanocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Prevalence of exon 15 BRAF mutations in primary melanoma of the superficial spreading, nodular, acral, and lentigo maligna subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

BRAF point mutations in primary melanoma show different prevalences by subtype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Absence of exon 15 BRAF germline mutations in familial melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

High BRAF mutation frequency does not characterize all melanocytic tumor types

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

BRAFE600-associated senescence-like cell cycle arrest of human naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

BRAF(E600) in benign and malignant human tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Low prevalence of RAS-RAF-activating mutations in Spitz melanocytic nevi compared with other melanocytic lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Prognostic significance of activated Akt expression in melanoma: a clinicopathologic study of 292 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

PTEN signaling pathways in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

A novel AKT3 mutation in melanoma tumours and cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the effective treatment of advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

21 January 2018

mTOR and cancer therapy

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Defining the role of mTOR in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Expression of c-met tyrosine kinase receptor is biologically and prognostically relevant for primary cutaneous malignant melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Scatter factor and the c-met receptor: a paradigm for mesenchymal/epithelial interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Downregulation of E-cadherin and Desmoglein 1 by autocrine hepatocyte growth factor during melanoma development

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Somatic activation of KIT in distinct subtypes of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Loss of AP-2 results in downregulation of c-KIT and enhancement of melanoma tumorigenicity and metastasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The Bcl-2 protein family: arbiters of cell survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Resistance to CD95/Fas-induced and ceramide-mediated apoptosis of human melanoma cells is caused by a defective mitochondrial cytochrome c release

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Conditional expression of exogenous Bcl-X(S) triggers apoptosis in human melanoma cells in vitro and delays growth of melanoma xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Loss of proapoptotic Bcl-2-related multidomain proteins in primary melanomas is associated with poor prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The inhibitors of apoptosis (IAPs) as cancer targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The X-linked inhibitor of apoptosis protein (XIAP) is up-regulated in metastatic melanoma, and XIAP cleavage by Phenoxodiol is associated with Carboplatin sensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Downregulation of Bcl-2, FLIP or IAPs (XIAP and survivin) by siRNAs sensitizes resistant melanoma cells to Apo2L/TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Microphthalmia-associated transcription factor (MITF) is required but is not sufficient to induce the expression of melanogenic genes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

MITF: master regulator of melanocyte development and melanoma oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Genome-wide loss of heterozygosity and copy number analysis in melanoma using high-density single-nucleotide polymorphism arrays.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Melanoma biology and new targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Apoptosis and melanoma chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Chemotherapy for metastatic melanoma: time for a change?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Treatment of metastatic malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Cutaneous melanoma: available therapy for metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Ipilimumab: a novel treatment for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Phase II trial of imatinib mesylate in patients with metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

A phase 2 study of vatalanib in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Rapamycin inhibits doxorubicin-induced NF-kappaB/Rel nuclear activity and enhances the apoptosis of melanoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Vertical inhibition of the mTORC1/mTORC2/PI3K pathway shows synergistic effects against melanoma in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Role and therapeutic potential of PI3K-mTOR signaling in de novo resistance to BRAF inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Resistance to selective BRAF inhibition can be mediated by modest upstream pathway activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

CCI-779 plus cisplatin is highly effective against human melanoma in a SCID mouse xenotranplantation model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Lifetime prevalence of uveal melanoma in white patients with oculo(dermal) melanocytosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Choroidal nevi in a white population: the Blue Mountains Eye Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Uveal and conjunctival malignant melanoma in denmark 1943-97: observed and relative survival of patients followed through 2002.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Prognostic factors following enucleation of 111 uveal melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Prognostic parameters in uveal melanoma: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Patterns of regional and distant metastasis in patients with conjunctival melanoma: experience at a cancer center over four decades

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Prognostic factors in primary malignant melanoma of the conjunctiva: a clinicopathological study of 256 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Activation of the MAPK pathway is a common event in uveal melanomas although it rarely occurs through mutation of BRAF or RAS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Effects of G-protein mutations on skin color

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Mutations in GNA11 in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

High frequency of submicroscopic hemizygous deletion is a major mechanism of loss of expression of PTEN in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Expression of the c-kit receptor in choroidal melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Prognostic implications of monosomy 3 in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

A potential role for TGFbeta in the regulation of uveal melanoma adhesive interactions with the hepatic endothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Acquired homozygosity (isodisomy) of chromosome 3 in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Deregulation of the Rb and p53 pathways in uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The prognostic value of cyclin D1, p53, and MDM2 protein expression in uveal melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

T1799A BRAF mutations in conjunctival melanocytic lesions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Developments in the management of uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Genotype-dependent sensitivity of uveal melanoma cell lines to inhibition of B-Raf, MEK, and Akt kinases: rationale for personalized therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

IMiDs: a novel class of immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The effect of imatinib mesylate (Glivec) on human tumor-derived cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Extracellular signal-regulated kinase-dependent proliferation is mediated through the protein kinase A/B-Raf pathway in human uveal melanoma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

VEGF-Trap: a VEGF blocker with potent antitumor effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Sunitinib: from rational design to clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

The PI3K/Akt and mTOR/P70S6K signaling pathways in human uveal melanoma cells: interaction with B-Raf/ERK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Expression of somatostatin receptors in uveal melanomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Targeted therapy for uveal melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

Dissociation of Erythema and p53 Protein Expression in Human Skin Following UVB Irradiation, and Induction of p53 Protein and mRNA Following Application of Skin Irritants

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2012.691472

10.1517/14728222.2012.691472

21 January 2018

Identifiers

DOI

1 reference

release_nrqib32cwzcuhiw2xmfq2fsjye

27 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nrqib32cwzcuhiw2xmfq2fsjye

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference